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Abstract
Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, 
either by clinical judgment and PSA testing, or using multivariate risk prediction tools. The use of multivariable risk pre-
diction tools can significantly reduce unnecessary systematic biopsies, without compromising the detection of clinically 
significant disease. Increasingly multi-parametric magnetic resonance imaging (MRI) is performed, not only in men with 
a persistent suspicion of prostate cancer after prior negative systematic biopsy, but also at initial screening before the first 
biopsy. The combination of MRI and multivariate risk prediction tools could potentially enhance prostate cancer diagnosis 
using multivariate MRI incorporated risk-based models to decide on the need for prostate MRI, but also using MRI results 
to adjusted risk-based models, and to guide MRI-directed biopsies. In this review, we discuss the diagnostic work-up for 
clinically significant prostate cancer, where the combination of MRI and multivariate risk prediction tools is integrated, and 
how together they can contribute to personalized diagnosis.
Keywords Prostate cancer · Biopsy · Magnetic resonance imaging (MRI) · Risk stratification · Multivariate risk prediction · 
Risk calculator · Nomogram
Introduction
Magnetic resonance imaging (MRI) is an increasingly useful 
tool for clinically significant prostate cancer detection and 
has recently come to the forefront in the diagnostic work-up 
in many countries [1–3]. Its utility has been demonstrated by 
multiple prospective studies including randomized clinical 
trials [4, 5] and multiple, systematic analyses that consist-
ently show improvements in biopsy avoidance, reductions 
in the detection of indolent disease and improved detection 
of clinically significant disease [6, 7]. Prospective multi-
center studies as the recently published ‘MRI-first’ [8] and 
‘4 M’ trials [9] show the beneficial effects in prostate cancer 
detection in biopsy-naïve men, when MRI is combined with 
systematic and targeted biopsies.
However, these studies do not directly address the ques-
tion on who benefits from the MRI approach. As for sys-
tematic biopsy, this is likely to be biopsy-naïve men with 
elevated serum PSA levels and/or abnormal digital rectal 
examinations, and those who are deemed to be at persistent 
elevated risk of harboring significant cancers despite prior 
negative or non-explanatory systematic biopsies. However, 
clear guidance cannot be derived from the available litera-
ture, because inclusion criteria for all MRI studies have been 
restricted to those with higher risks, and studies evaluating 
the benefits of MRI according to clinical risk factors are few 
[10, 11]. The 2019 EAU prostate cancer guideline recom-
mends not limiting biopsies to pre-specified PSA thresholds, 
as there are many other factors (e.g., symptoms, age, race, 
family history, PSA kinetics, and digital rectal examination 
findings) that also inform on the decision to biopsy [1].
To aid decision-making with regard to the need for 
biopsy, multivariate risk-based prediction tools have been 
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developed to assess the likelihood of having clinically signif-
icant prostate cancer [12]. These risk calculators stratify men 
for further biopsy testing or clinical monitoring using readily 
available clinical parameters. Multivariate risk prediction 
tools can also be used to decide on the need for prostate MRI 
by enriching patient selection on one hand and avoiding MRI 
testing on the other [13, 14]. Thereafter, adding anatomical 
and functional information after MRI to multivariate risk-
calculator assessments refines the underlying risk of clini-
cally significant cancer and thereby modulates the need for 
biopsy, also informing on biopsy methods so as to increase 
biopsy yields, by identifying targets that are likely to harbor 
clinically significant disease [15, 16].
In this review, we conceptualize the diagnostic work-up 
of patients suspected of having clinically significant prostate 
cancer using combinations of MRI and multivariate predic-
tion tools and explore how they together can enable indi-
vidualized risk-adapted diagnostic strategies.
Risk assessments
Risk assessments for prostate cancer diagnosis aim to iden-
tify disease-related factors that have the potential to cause 
disease or increase the risk of developing disease. Factors 
that enhance disease likelihood include older age, family 
predisposition, African ethnicity, elevated PSA serum levels 
(or derivatives), abnormal rectal examination, and genetic 
factors. These risks require weighting for the target con-
dition, which is preferably clinically significant prostate 
cancer. To integrate multiple risk factors, multivariate risk-
based prediction tools (i.e., risk calculators or nomograms) 
have been developed. Risk calculators provide numerical 
outputs that indicate higher likelihood of prostate cancer 
(therefore needing biopsy), and, in contradistinction, identify 
which men do not need further testing, so avoiding further 
testing.
This individualized risk-adapted strategy for prostate can-
cer detection enables the balancing of benefits versus harms 
[17, 18]. It is important to identify only those men that are 
likely to benefit from timely diagnoses. Benefit is, there-
fore, the detection and appropriate treatment of clinically 
significant prostate cancer. The harms include redundant 
(unnecessary) testing and the likelihood of having compli-
cations of testing (such as rectal bleeding, urine retention, 
bacteremia, and urosepsis). Remembering also that many of 
the cancers detected may never become clinically evident, 
thereby leading to over-diagnoses and over-treatments [17], 
thus contributing to harms.
It is important to develop and employ individual-
ized risk-adapted strategies based on reliable risk pre-
diction tools. Increasingly, the diagnostic work-up 
of prostate cancer detection is shifting towards using 
multivariate decision support tools that facilitate risk-
adapted approaches [1]. Decision-making based on mul-
tivariate risk prediction tools can overcome the limitations 
of PSA-based screening (Fig.  1a). Furthermore, when 
multivariate risk prediction tools (Fig. 1b) and mpMRI 
(Fig. 1c) are utilized in the diagnostic work-up, several 
combinations become possible each of which clarifies 
underlying risk, indicating the need for and type of biopsy 
that maximizes benefits and minimizes harms (Fig. 1d–f). 
In this paper, we discuss each strategy evaluating diagnos-
tic benefits and harms as defined above.
Risk assessments based on PSA values only
The fact that PSA is a well-developed, easy to implement, 
and a cheap test makes PSA the mainstay in the decision 
for further clinical work-up. At opportunistic screening, 
informed men who request an early diagnosis should be 
given a PSA test and undergo a digital rectal examination 
(Fig. 1a) [19].
The occurrence of Gleason score ≥ 3 + 4 (or ISUP grad-
ing ≥ 2) prostate cancer even at low PSA levels precludes the 
setting up of an optimal PSA threshold for detecting non-
palpable but clinically significant cancers [20]. Any PSA 
threshold involves a trade-off between sensitivity and speci-
ficity. Lowering the PSA cut-off value improves test sensi-
tivity, but reduces specificity, leading to more false-positive 
tests and unnecessary interventions adding to harms. As a 
result of these limitations, using PSA values alone has fallen 
out of favor, leading to the introduction of multivariate risk 
prediction tools into clinical practice [1].
Risk assessment based on multivariate risk 
prediction tools
Biopsy indications based on PSA cut-off values can be 
modified using clinical variables such as the initial PSA, 
PSA velocity, free/total PSA ratio, other serum kallikreins, 
prostate volume, and other predictors such as age, family 
history, and race alone or in combination within multivariate 
risk prediction tools [21]. Furthermore, urine markers (i.e., 
PCA3 and SelectMDx), and even genomic analyses could 
aid in risk stratification for biopsy indication.
Multivariate risk prediction models for prostate cancer 
diagnosis focus on correctly diagnosing patients with clini-
cally significant prostate cancer, providing prognostic esti-
mates thus aiding in clinical decision-making.
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Fig. 1  Diagnostic flowcharts 
of men with elevated prostate-
specific antigen (PSA) and/or 
abnormal digital rectal examina-
tion (DRE), with combinations 
of risk stratification w/o prostate 
MRI. Risk assessment with a 
PSA only, b multivariate risk 
prediction tools only, c prostate 
MRI only, and d multivariate 
risk prediction tools: when 
systematic biopsy is indicated 
subsequently a prostate MRI 
is performed to indicate a 
combined targeted biopsy, e 
multivariate risk prediction 
tools incorporating prostate 
MRI for biopsy-decision man-
agement (systematic, targeted, 
or both), and f multivariate risk 
prediction tools (step 1) may 
indicate systematic biopsy and 
subsequently a prostate MRI 
is performed. Based on the 
outcome parameters of prostate 
MRI incorporated in MRI-
multivariate risk prediction 
tools, these tools may navigate 
into further biopsy testing or 
into deferring biopsy testing. 
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Performance measures: discrimination, calibration, and net 
benefit
Discrimination (i.e., separating people with disease from 
without disease), calibration (i.e., agreement between 
observed outcome and predicted risk), and net benefit (i.e., 
true positives minus false positives) are important indicators 
for evaluating the performance of risk prediction tools [22].
Accurate predictions discriminate between those with and 
those without clinically significant prostate cancer. Good 
discrimination means that men with significant cancer will 
consistently have higher predicted risks than those men 
without significant disease. Discrimination is important in 
diagnostic settings, because we want to separate men with 
and without clinically significant prostate cancer. To indi-
cate the discriminative ability of risk prediction models for 
a binary outcome, the area under the Receiver-Operating 
Characteristic (ROC) curve is commonly used, which plots 
the sensitivity (true positive rate) against 1—(false-positive 
rate) for consecutive cut-offs for the probability of signifi-
cant disease. In general, discrimination is not dependent on 
disease prevalence. Evaluation of prediction models should 
not rely solely on ROC curves, but should assess both dis-
crimination and calibration.
Calibration refers to the agreement between observed 
outcomes and predictions. Calibration is more important in 
prognostic settings, because we would like to more precisely 
predict the risk of clinically significant prostate cancer. Cali-
bration concerns itself directly with the estimated probabili-
ties or predictive values. The positive predictive value is 
defined as the probability of clinically significant disease 
given a positive test result, and the negative predictive value 
is the probability of no significant disease given a negative 
test result. When a risk score is used, the continuous analog 
is the probability of disease given the value or range of the 
score. An assessment of calibration directly compares the 
observed and predicted probabilities, for which the disease 
prevalence is very important.
Some models over-/under-estimate the actual risk (have 
poor calibration), but can still separate those with disease 
and without disease (good discrimination). The reverse can 
also happen where a model has good calibration, but cannot 
discriminate between those with and without disease. Ide-
ally, clinically useful models should be well calibrated and 
with high discrimination.
Net Benefit is a commonly used metric that weights the 
relative consequences in terms of the risk threshold at which 
a urologist would advise for further invasive diagnostic test-
ing or treatment. Net benefit combines the number of true 
positives and false positives into a single “net” number. 
Conceptually, net benefit in business would be analogous 
to income minus expenditure [23]. In prostate cancer, true 
positives are clinically significant prostate cancer found; 
false positives are unnecessary prostate biopsies performed 
(hence ‘benefit-to-harm’ ratio). In prostate cancer diagnosis, 
we weigh the benefit of correct diagnosis strongly over the 
harms of negative biopsies.
The “exchange rate” reflects how many biopsies are 
acceptable to find one significant cancer [24]. In urological 
practice, there is no general agreement on this exchange rate 
or risk threshold for biopsy, so it is important to evaluate 
net benefit over a range of reasonable exchange rates or risk 
thresholds to advise men at risk and their urologists.
Risk thresholds
Risk-calculator outputs are on a sliding scale, indicating the 
likelihood of any cancer and clinically significant cancers 
(the definition of the latter often depends on the risk cal-
culator). Often times, this continuum of estimated risks is 
categorized into low (not elevated), intermediate, and high 
(requiring biopsy) [25], thus helping to clarify an indi-
vidual’s potential risk for clinically significant cancer, and 
thereby enabling the identification of only those men need-
ing further testing, and contrarily identifying men at non-
elevated risk and so reducing the number of unnecessary 
biopsies (Fig. 1b). Threshold values for biopsy, however, 
vary between risk calculators [12].
Risk calculators
There are several risk calculators designed for clinical use 
[25–32]. The European Randomized Study of Screening 
for Prostate Cancer-based Risk Calculator (RPCRC) [25] is 
applicable to Northern European populations and the North 
American Prostate Biopsy Collaborative Group (PBCG) 
Risk Calculator [31] is applicable to a more diverse radial 
group. Only four calculators are able to separately predict 
clinically significant prostate cancer (RPCRC [25], Pros-
tate Cancer Prevention Trial (PCPT) 2.0 with or without 
(±) freePSA [30], and Sunnybrook RC [32]). Of these, only 
the RPCRC and PCPT 2.0 (± freePSA) have been externally 
validated in more than five studies [12].
Prediction of clinically significant prostate cancer
Four risk calculators have been shown to be able to predict 
the presence of clinically significant prostate cancer using 
biopsies, with areas under the curve (AUC; discrimination 
measure) values ranging from 0.71 to 0.77 in head-to-head 
comparisons, using patient data from a multicenter Euro-
pean and Australian population [21]. The RPCRC showed 
the highest discrimination [AUC 0.77 (95% CI: 0.73, 0.80)] 
indicating its benefit for daily practice [21]. Adjusting 
the calibration to prevalence improves the value of incor-
porating multivariable risk prediction tools in clinical 
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decision-making. These results confirmed earlier analyses 
on the use of multivariable prediction tools [12] for pros-
tate cancer diagnosis. Taken together, these results support 
the clinical use of multivariable risk prediction tools for the 
diagnostic work-up of men with suspected clinically signifi-
cant prostate cancer. Although some risk calculators have 
greater efficiency than others, specific recommendations on 
which calculator to use is not stated within guidelines [1, 3]. 
Therefore, choice on which one to use depends on the mix 
of the local population and the clinical parameters available 
for data input.
Prostate assessment by MRI
From five‑point Likert scale to binary MRI decision 
model
The PI-RADS (Prostate Imaging-Reporting and Data Sys-
tem) method for evaluating prostate MRI is designed to be 
used for the evaluation of patients at risk of having clinically 
significant prostate cancer, to decide who requires biopsy 
[33]. PI-RADSv2 assessments uses a five-point category 
scale indicating the likelihood (probability) that a combina-
tion of predefined MRI findings correlates with the presence 
of a clinically significant cancer for each identified lesion in 
the prostate gland [34]. A highly desirable quality of MRI 
is its high negative predictive value for clinically signifi-
cant cancer [35, 36], meaning that men with negative tests 
may not need biopsies (Fig. 1c) [4, 5]. In practice, a binary 
MRI decision model for determining biopsy need has been 
introduced, with MRI-negative tests defined as PI-RADS 
assessment category 1 or 2, and MRI-positive tests defined 
as PI-RADS assessment categories 3, 4, or 5. For detecting 
clinically significant prostate cancer, this binary MRI deci-
sion model has been shown to have high sensitivity (0.91; 
95% CI: 0.83, 0.95) and low specificity (0.37; 95% CI: 0.29, 
0.46), when referenced to template-guided mapping verifica-
tion biopsies [6]. False positives have been shown to occur 
predominantly within PI-RADS category 3 and 4 lesions, 
and less so in category 5 lesions [37, 38].
From binary MRI decision model to four‑point 
MRI‑based risk assessment
Detection rates for clinically significant prostate cancer 
according to PI-RADS assessment categories vary signifi-
cantly within and between patient cohorts (biopsy-naïve, 
prior negative biopsy, and prior positive biopsy in active 
surveillance) [37] and between studies [38]. The yield 
of clinically significant cancers per likelihood category 
depends on multiple factors, including histologic definitions 
employed (with higher yields for definitions that incorporate 
both tumor volume and tumor grade), and with the use of 
combined systematic biopsy cores with MRI-directed biopsy 
cores. Nevertheless, all published data consistently showed 
higher yields of clinically significant cancer with higher 
PI-RADS categories. For PI-RADS categories 3, 4, and 5 
in biopsy-naïve men, the estimated detection rates of ISUP 
grade ≥ 2 (21%, 39%, and 73%) and ISUP grade ≥ 3 (6%, 
16%, and 43%) showed stepwise higher yields [37]. The 
ISUP grade 1 (18%, 23%, and 19%) appears to decline over 
the PI-RADS categories 3, 4, and 5 [37].
It is possible to change the five MRI categories to a four-
point category scale of risk assessment; viz low risk (PI-
RADS 1 or 2), intermediate risk (PI-RADS 3), high risk 
(PI-RADS 4), and very high risk (PI-RADS 5). For these 
MRI risk categories, it is possible to ascribe different actions 
on the need for and type of biopsy such as those recom-
mended by the EAU 2019 prostate cancer guidelines and the 
PI-RADS steering committee pathway white paper [1, 39].
MRI performance and disease prevalence
Because PSA is widely used for indicating the need for 
biopsy, we should acknowledge that literature documented 
MRI utilities are only applicable to disease prevalences 
applicable to men whose risk was deemed to be sufficiently 
high to warrant an MRI before biopsy. The recent systematic 
analysis of Moldovan et al. indicated that in 48 studies (with 
9613 patients), who underwent MRI, the median prevalence 
for any cancer was 50% [interquartile range (IQR), 36–58%] 
and was 33% (IQR, 28–37%) for significant cancer [36]. In 
the Cochrane analysis, focusing on biopsy-naïve men (with 
5219 in 20 studies), the prevalence of any cancer was 53% 
(95% CI: 49–58%) and was 28% (95% CI: 24–33%) for sig-
nificant cancer [6].
Disease prevalence impacts the clinical utility of pros-
tate MRI. Take for example the PAIREDCAP study [40] 
which had a very high prevalence of ISUP grade ≥ 2 can-
cers (61%) in biopsy-naïve men detected by a combined 
approach of MRI-targeted and systematic biopsies. This 
overall 61% (182/300 men) prevalence resulted in a 70% 
(174/248 men) ISUP grade ≥ 2 detection rate in men with 
a positive MRI scan, with a marginal non-significant added 
benefit of targeted biopsies; the detection rates for targeted 
biopsy and systematic biopsy were 62% (154/248) and 60% 
(149/248) (P = 0.70), respectively. In comparison, the pooled 
prevalence in biopsy-naïve men was 28% in the Cochrane 
meta-analysis [6]. This 28% (95% CI: 24–33%) prevalence 
resulted in a 44% (95% CI: 39–50%) ISUP grade ≥ 2 detec-
tion rate in men with a positive MRI scan with a significant 
added benefit of targeted biopsies; the detection rates for 
targeted biopsy and systematic biopsy were 39% (95% CI: 
33–46%) and 34% (95% CI: 28–41%) (P = 0.03), respec-
tively. Therefore, when there is a very high risk of clinically 
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significant prostate cancer, the benefit of a positive MRI 
decreases in comparison to a lower but elevated risk.
In MRI-negative men, the detection of ISUP grade ≥ 2 
cancers by systematic biopsy was 15% (8/52 men), which 
was also almost double in comparison to 8% (95%CI: 
6–12%) in the Cochrane review. As a result, in the Cochrane 
review, 12–13 MRI-negative men need to be biopsied to 
detect one man with ISUP grade ≥ 2 cancer, which maybe 
consider as an unfavorable exchange rate, whereas for the 
PAIREDCAP study population, this number is 6–7 men, 
which is more acceptable. Therefore, when there is an ele-
vated risk of clinically significant prostate cancer, a negative 
MRI should not be used to avoid biopsy (Fig. 1d) because of 
resulting increases in the rate of missed significant prostate 
cancer [36].
Similarly, the utility of MRI at lower risk profiles such 
as in population screening also cannot be drawn from the 
published data. In fact, we need to be aware that in men 
with lower risk profiles, the false-positive rate of MRI 
will increase [41], and the low specificity of MRI will 
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result in increased numbers of false positives. This could 
unnecessary increase biopsy rates impacting adversely on 
the benefit-to-harms ratio.
We, therefore, need to create new risk categories that 
consider both the likely prevalence of clinically signifi-
cant prostate cancer and the results of MRI scans, when 
choosing which men need biopsy and who can be safely 
monitored. These revised MRI integrated risk categories 
can then be used to also indicate biopsy method, route, 
and number of cores, to maximize benefits and reduce 
harms. These will differ by geographic population, by 
institutional preferences, and between patient cohorts 
(first biopsy, repeat biopsy, and active surveillance).
Integrating multivariate risk prediction tools 
with MRI
There are multiple ways in which multivariate risk predic-
tion tools can be combined with MRI results to improve 
prostate cancer diagnosis. These include (1) using predic-
tion tools to indicate the need for an MRI, (2) to indicate the 
need for biopsy particularly for equivocal cases after MRI 
results, and (3) to indicate the extent of and the approaches 
for tissue sampling.
Indicating need for MRI
Multivariate prediction tools can be used to indicate the need 
for an MRI (Fig. 1d). The purpose of upfront MRI is two-
fold: (1) to mitigate the unrestraint use of MRI testing [14], 
and (2) to enrich the population prevalence to a high enough 
level, where MRI has been shown to have clinical utility 
as discussed above. When multivariate risk prediction tools 
indicate that risk is not high enough to perform a biopsy or 
MRI, avoiding MRI will result in limiting the false-positive 
outcomes of MRI testing [42], and, therefore, reduce the 
number of biopsies undertaken. This means that some clini-
cally significant cancers will not be immediately diagnosed 
(just as in the pre-MRI era but with lesser frequency), requir-
ing robust follow-up regimens to catch emerging over time.
When multivariate risk prediction tools indicate the need 
for systematic biopsy, an MRI should be undertaken in men 
likely to benefit most from a PI-RADS compliant multi-par-
ametric MRI scan. This typically includes asymptomatic men 
with PSA levels between 2 and 10 ng/ml [1]. A comprehen-
sive scanning approach may not be needed for symptomatic 
men with a very high risk of prostate cancer based on positive 
digital rectal examination, very high PSA levels, and multi-
variable risk-calculator estimates [10]; for these men, a more 
limited approach without contrast medium may be sufficient.
Indicating need for biopsy
Magnetic resonance imaging results can help to refine risk 
stratification (by providing a more accurate prostate volume 
compared to clinical estimates and by the PI-RADS suspi-
cion category) (Figs. 2, 3). If the risk remains high despite a 
negative MRI result, MRI results will not affect the number 
of men undergoing systematic biopsies. Thus, there will be 
little impact on over-diagnosis rates in men with negative 
scans [40].
The prevalence of clinically significant cancer in inter-
mediate PI-RADS category 3 patients varies from one in 
five (21%) to one in six (16%), depending on previous 
Fig. 2  Case example: a 69-year-old man with a PSA of 6.8  ng/ml. 
Digital rectal examination (DRE) was normal, and transrectal ultra-
sound (TRUS) showed a prostate volume of 55 ml, without any hypo-
echoic lesions found on ultrasound. The PSA density was 0.12 ng/ml2 
(6.8/55). Does this biopsy-naive man deserve an MRI and/or biopsy? 
(1) In this biopsy-naïve man, the chance of finding any prostate can-
cer with further testing is 32%, based on the ERSPC-RC#2 (includ-
ing PSA only in biopsy-naïve men) [49], suggesting a systematic 
biopsy is justified. (2) The chance of finding any prostate cancer and 
clinically significant prostate cancer with further testing is 16% and 
3%, respectively, based on the ERSPC-RC#3 (including PSA, DRE, 
TRUS, and TRUS volume) [49] (a). Including DRE, TRUS, and 
TRUS volume in the risk calculation gives a lower risk estimation 
of having a biopsy-detectable clinically significant prostate cancer. 
The next action should be guided by the chance of having a positive 
biopsy: (1) less than 12.5% → no prostate biopsy (and no MRI); (2) 
between 12.5 and 20.0% → consider biopsy (and MRI), depending on 
co-morbidity and more than average risk on high grade prostate can-
cer (more than 4%); (3) 20.0% or more → prostate biopsy (and MRI). 
In this man, a systematic biopsy is justified, based on the ERSPC-
RC#3. (3) A 3T multi-parametric MRI was performed (b), showing 
a large prostate gland with compression of the peripheral zone, and 
a suspected lesion for clinically significant prostate cancer at the left 
peripheral zone dorsolateral, at the mid-prostate, 12 × 4 mm, without 
extraprostatic extension or seminal vesicle invasion; PI-RADS assess-
ment score 4 (4/4/+), based on low signal intensity on T2w-imaging 
(4), high signal intensity on DWI (b-800 and b-2000 (calculated) 
combined with low signal intensity on ADC (4), and focal enhance-
ment (+). Based on high yields of clinically significant prostate can-
cer (> 30–40%) in an MRI lesion with a PI-RADS assessment score 
4 (Sects.  3.2 and 4.2) [37], a targeted biopsy is indicated. (4) The 
chance of finding any prostate cancer and clinically significant pros-
tate cancer with further testing is 20% and 9%, respectively, based on 
the MRI-ERSPC-RC#3 (including PSA, DRE, TRUS, TRUS volume, 
and MRI PI-RADS score) [49] (c). In this man, a systematic and tar-
geted biopsy is justified. Biopsy considerations the morphology of the 
suspected peripheral zone lesion is long and small; targeted cores of 
the lesions combined with targeted cores from the penumbra (focal 
saturation) could be sufficient. Biopsy protocol and pathology find-
ings Protocolled 12 systematic biopsies and 2 targeted biopsies were 
performed under MRI/US fusion guidance. 12 systematic biopsies 
showed benign prostatic tissue only. 2 targeted biopsy cores showed 
Gleason score 3 + 4 (ISUP group 2) with 3 mm and 4 mm maximum 
cancer core length, without cribriform or intraductal growth pattern
◂
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biopsy status [37]. Although this PI-RADS 3 category sig-
nificant prostate cancer prevalence is low in comparison to 
PI-RADS category 4 (range 33–39%) and 5 lesions (range 
60–73%) [37], the proportion of men with significant dis-
ease is not inconsequential. As a result, in some clinical 
practices, the decision to biopsy PI-RADS category 3 men 
is influenced by a range of clinical factors including PSA 
kinetics, PSA density, previous biopsy results, and patient 
preferences [43, 44]. This argues for including multivari-
ate prediction tools for biopsy decision-making in men 
with intermediate PI-RADS 3 category lesions.
For high-risk men, positive MRI results can aid in the 
choice of biopsy methods (targeted with or without sys-
tematic biopsy), to maximize diagnostic yields of signifi-
cant cancers [13, 14] as discussed in the next section.
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Indicating biopsy extent and approaches
There is robust debate about how to best use MRI results; to 
increase yields of significant cancers versus reducing over-
diagnoses of insignificant cancers. Magnetic resonance 
imaging results can be used in multiple ways [45]. (1) The 
‘combined biopsy pathway’ where patients with negative 
MRI undergo scheduled systematic biopsy and men with 
positive MRI undergo both systematic and MRI-directed 
biopsy maximizes the diagnostic yields of significant cancers 
[8, 9]. (2) The ‘MRI-pathway’ is distinct in that men with 
negative scans are not biopsied at all, and men with positive 
scans undergo only MRI-directed biopsies (without system-
atic cores). The advantage of the MRI-pathway is to reduce 
the number of men needing biopsies and to reduce the total 
number of biopsy cores taken, thus helping to reduce over-
diagnoses of insignificant disease. A mixed biopsy approach 
can also be used.
The combined biopsy pathway uses the intrinsic MRI 
localization information to influence biopsy approaches. The 
location and size of MRI lesions can indicate the preference 
for limited MRI-directed biopsy cores only, or the need for 
additional focal saturation biopsy cores, or the additional 
need for systematic biopsy cores (Fig. 1e) as per the recom-
mendations of the 2019 EAU guidelines and the PI-RADS 
Committee Pathway white paper [1, 39].
For example, large PI-RADS category 5 lesions might be 
biopsied by a limited number of targeted biopsy cores, omit-
ting systematic biopsies. In men with PI-RADS category 
3 or small category 4 prostate lesions, the combined use 
of elevated risk-calculator findings and MRI location infor-
mation may indicate the need for using MRI-targeted and 
systematic biopsy approaches to gain maximal diagnostic 
yields. When over-diagnosis is a concern, for example in 
biopsy-naïve men with PI-RADS category 3 or small cat-
egory 4 prostate lesions, biopsies using MRI-targeted and 
focal saturation biopsy approaches may be sufficient [39]. 
In men with PI-RADS category 3, lesions with low clinical 
suspicion on risk calculator or on PSA density will likely not 
be biopsied at all [44]. On the other hand, men with non sus-
picious MRI who are deemed to be at high risk using clinical 
and biochemical parameters would need to be biopsied in a 
systematic manner, even in the absence of definable MRI tar-
gets. Those men at low-risk using clinical and biochemical 
parameters and negative MRI scans can safely avoid biopsy 
and could be discharged from urological care.
In each of the above clinical scenarios, underlying risk 
and imaging findings are subjectively combined for decid-
ing on biopsy need and approach. Given that it is possible 
to predict underlying risk using multivariate prediction tools 
and MRI assessments, a combined more objective approach 
becomes possible (Fig. 4) to help decide on biopsy actions 
for combined risk profiles as discussed in the next section.
Combining multivariable risk prediction tools 
including MRI
Multivariate risk prediction tools that include MRI suspi-
cion scores also have the potential to substantially lower 
the number of biopsies and the detection of clinically 
insignificant prostate cancer, at a low price of missing 
some clinically significant prostate cancer. The trade-
off between significant cancer detected and missed, in 
Fig. 3  Case example. a 72-year-old man has a PSA of 5.8 ng/ml with 
lower urinary tract symptoms. Digital rectal examination (DRE) 
showed a right-sided abnormal prostate, classified as cT2 tumor. 
Transrectal ultrasound (TRUS) showed a prostate volume of 89  ml, 
with a right-sided hypo-echoic lesion found on ultrasound. The 
PSA density was 0.07  ng/ml2 (5.8/89). Does this biopsy-naive man 
deserve an MRI/biopsy? (1) In this biopsy-naïve man, the chance of 
finding any prostate cancer with further testing is 29%, based on the 
ERSPC-RC#2 (including PSA only in biopsy-naïve men) [49], sug-
gesting a systematic biopsy is justified. (2) The chance of finding 
any prostate cancer and clinically significant prostate cancer with 
further testing is 25% and 14%, respectively, based on the ERSPC-
RC#3 (including PSA, DRE, TRUS, and TRUS volume) [49] (a). In 
this man, a systematic biopsy is strongly recommended, based on the 
ERSPC-RC#3. (3) A 3T multi-parametric MRI was performed (b), 
showing a large prostate with compression of the peripheral zone, 
and a suspected lesion for clinically significant prostate cancer at the 
right peripheral zone dorsolateral, at the apex, 17 × 15 mm, without 
extraprostatic extension or seminal vesicle invasion; PI-RADS assess-
ment score 5 (5/5/+), based on low signal intensity on T2w-imaging 
(5), high signal intensity on DWI (b-800 and b-2000 (synthetic/cal-
culated) combined with low signal intensity on ADC (5), and focal 
enhancement (+). Based on high yields of clinically significant 
prostate cancer (> 70%) in an MRI lesion with a PI-RADS assess-
ment score 5 (Sect.  3.2 and 4.2) [37], a targeted biopsy is strongly 
recommended in this biopsy-naïve man. A separate suspected lesion 
in the dorsal left peripheral zone in the apex categorized as PI-RADS 
score 4 (4/4/−) suggests multifocal prostate cancer. (4) The chance 
of finding any prostate cancer and clinically significant prostate can-
cer with further testing is 70% and 45%, respectively, based on the 
MRI-ERSPC-RC#3, including PSA, DRE, TRUS, TRUS volume, and 
MRI PI-RADS score [49] (c). In this man, a systematic and targeted 
biopsy is advised. Biopsy considerations The morphology of the sus-
pected peripheral zone lesion in the right apex is large; targeted cores 
of the lesion will most likely hit the lesion. To limit undersampling, 
up to five cores might be sufficient [50]. The morphology of the sus-
pected peripheral zone lesion in the left apex is small. Although tar-
geted cores of the lesion most likely will hit the lesion, still, there is 
reasonable chance of undersampling or missing the lesion. A focal 
saturation biopsy might be most accurate [39]. Biopsy protocol and 
pathology findings Protocolled 12 systematic biopsies and 2 targeted 
biopsies in each suspected lesion were performed under MRI/US 
fusion guidance. Right-sided 6 systematic biopsies showed in 3 cores 
Gleason score 3 + 4 (ISUP group 2) with 1 mm, 10 mm, and 3 mm 
maximum cancer core length. Right-sided 2 targeted biopsies showed 
in 2 cores Gleason score 3 + 4 (ISUP group 2) with 14 mm and 7 mm 
maximum cancer core length, without cribriform or intraductal 
growth pattern. Left-sided 6 systematic biopsies showed benign pros-
tatic tissue. Left-sided 2 targeted biopsies showed in 2 cores Gleason 
score 3 + 3 (ISUP group 1) with 6 mm and 1 mm maximum cancer 
core length, without cribriform or intraductal growth pattern
◂
 World Journal of Urology
1 3
combination with the avoided unnecessary biopsies (net 
benefit), depends on the chosen risk thresholds for biopsy 
(exchange rates) as discussed above. In the current con-
text, this is the probability threshold used to determine 
whether a patient is classified as being positive or nega-
tive for significant prostate cancer and, therefore, needs 
biopsy [23]. In biopsy-naïve men, higher net benefits are 
obtained at risk thresholds above 10% in MRI-multivariate 
risk prediction models [42]. That is, in a man with an MRI, 
adjusted multivariate risk calculator of > 10% likelihood 
of cancer is more likely to benefit from biopsy than not 
(Fig. 1e).
When multivariate risk prediction models are used, the 
calculated risk is a continuum. For clinical practicality, 
thresholds for performing biopsy need to be defined for 
multivariate risk prediction tools that include MRI results 
[15, 16, 46–48]. Since multivariate risk prediction models 
incorporating MRI results have not yet been validated, these 
model thresholds are not yet available in the literature.
To bridge this knowledge gap, a matrix table is, there-
fore, proposed to categorize men with different risk profiles, 
based on validated multivariate risk prediction tools and on 
MRI risk assessments (Fig. 4). The continuum of estimated 
risks in multivariate risk prediction tools is categorized 
into low (not elevated), intermediate, and high (requiring 
biopsy). The MRI risk assessment is categorized into low 
(PI-RADS 1 or 2), intermediate (PI-RADS 3), high (PI-
RADS 4), and very high (PI-RADS 5). Each cell within the 
MRI risk assessments on imaging features indicang 
likely prevalence of clinically significant prostate cancer 
increasing prevalence on targeted & systemac biopsies  
MRI 
suspicion 
score 
PI-RADS 1-2 PI-RADS 3 PI-RADS 4 PI-RADS 5 
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Fig. 4  Matrix table based on the validated ERSPC-based Rotterdam 
prostate cancer risk calculator (RPCRC) and on MRI risk assess-
ments. The continuum of estimated risks of having a biopsy-detecta-
ble prostate cancer in the RPCRC is categorized into low (no elevated 
risk; less then 12.5%), intermediate (elevated risk; between 12.5 and 
20%), and high (elevated risk; 20% or more). Men with high risk of 
having a biopsy-detectable prostate cancer require biopsy. Also men 
with intermediate risk combined with a more than average risk on 
clinically significant prostate cancer (more than 4%) require biopsy 
[25]. Clinically significant prostate cancer in RPCRC is defined 
as any Gleason ≥ 4 grade, or primary and secondary Gleason ≤ 3 
with ≥ 50% positive cores or total cancer core length of ≥ 20 mm [25]. 
The MRI risk assessment is categorized into low (PI-RADS 1 or 2), 
intermediate (PI-RADS 3), high (PI-RADS 4), and very high risk (PI-
RADS 5) of having a biopsy-detectable clinically significant prostate 
cancer. Each cell ascribes a different biopsy action. This matrix table 
bridges the gap to new thresholds of developing and not-yet validated 
MRI prediction tools and may guide biopsy-decision management on 
individual patients in the increasingly complex, multivariate approach 
of prostate cancer diagnosis
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matrix has an ascribed biopsy action, taken from the recom-
mendation of the EAU 2019 prostate cancer guidelines and 
the PI-RADS steering committee pathway white paper [1, 
39]. This proposal may guide biopsy-decision management 
on an individual basis in the increasingly complex approach 
of prostate cancer diagnosis as illustrated in Figs. 2 and 3.
Clearly, multivariate risk prediction tools will need to be 
adjusted when the use purpose is changed. As already men-
tioned, adjustments to thresholds will likely be needed for 
deciding on biopsy strategies after MRI to optimize net ben-
efits (Fig. 1e). However, adjustment will be different when 
using them for deciding on the need for MRI (Fig. 1d), for 
decision to biopsy and biopsy type (e.g., focal saturation 
biopsy cores, or the additional systematic biopsy) (Fig. 1e), 
or at both for the need of MRI and decision to biopsy and 
biopsy type (Fig. 1f). Threshold adjustments will also be 
required to address changing risk-over-time. For example, in 
active surveillance if the initial low risk or intermediate risk 
is stable over time on multivariate analysis, the indication 
to further (biopsy) testing may be deferred. The advantages 
and disadvantages of three variations of mpMRI in combina-
tion with multivariate risk prediction tools discussed above 
(Fig. 1d–f) are summarized in Table 1.
Conclusion
Multivariate risk prediction tools used before MRI support 
physicians and patients deciding on the need for MRI before 
a biopsy consideration. The major benefit of pre-biopsy 
MRI in the diagnostic work-up is to promote individualized 
risk-adapted approaches for biopsy-decision management. 
The current benefits of pre-biopsy MRI for prostate cancer 
diagnostic work-up presuppose a high prevalence of clini-
cally significant cancer. Multivariate risk prediction tools in 
which MRI results are incorporated can support physicians 
and patients in biopsy decision-making in appropriately cho-
sen patients. Several clinical scenarios incorporating MRI 
are conceivable. Each diagnostic approach has net-benefit 
trade-offs between benefits and harms, based on improved 
diagnostic yields and reduced biopsy testing and reduced 
detection of indolent prostate cancer. Further data on the 
utility of multivariable risk prediction models that incorpo-
rate MRI information are awaited.
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